Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Sponsors › Genomics: Clinical Implementation › BioReference Labs' GenPath to Participate in NCI-MATCH

BioReference Labs' GenPath to Participate in NCI-MATCH

Aug 28, 2018
|
staff reporter

NEW YORK (360Dx) – BioReference Laboratories' GenPath Oncology Diagnostics division will participate in the National Cancer Institute's Molecular Analysis for Therapy Choice (NCI-MATCH) trial.

BioReference Labs signed a collaboration agreement with the National Cancer Institute and ECOG-ACRIN Cancer Research Group, which is coordinating the trial, BioReference parent company Opko Health announced today.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

What's Popular?

In Clinical Lab Management

  1. Lab Stakeholders Welcome Biden Moves on COVID-19 Testing, Suggest Additional Steps

    Premium

  2. SARS-CoV-2 Test Pooling Hampered by High Positive Rates, Logistical Hurdles

    Premium

  3. Hamilton Storage, Harvard Spinout Rhinostics Partner for High-Throughput Sample Processing

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.